Ou Yangwen, Zhang Cuiping, Yao Miaoen, Wang Lei
Department of Cardiovascular Medicine, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Evid Based Complement Alternat Med. 2019 Aug 21;2019:3719596. doi: 10.1155/2019/3719596. eCollection 2019.
Cardiovascular disease (CVD) is one of the three major threats to human health identified by WHO. Dyslipidemia, hypertension, diabetes, and obesity are well established as common CVD risk factors. However, controversies exist on the effects of gut flora on cardiovascular disease (CVD). Current evidence suggests that gut microbiota is a double-edged sword for CVD risk, and its effects are largely determined by the metabolites of the gut microbiota. Trimethylamine N-oxide (TMAO), as one of the metabolites of gut flora, is consistently associated with higher CVD risk. A few studies have emerged providing early evidence about the safety and efficacy of traditional Chinese medicine (TCM) in treating cardiovascular diseases by regulating gut flora. In this article, we review and interpret the existing evidence as well as explore the potential of intestinal flora as novel therapeutic targets of traditional Chinese medicine for the prevention of cardiovascular disease (CVD).
心血管疾病（CVD）是世界卫生组织确定的对人类健康的三大主要威胁之一。血脂异常、高血压、糖尿病和肥胖已被确认为常见的心血管疾病风险因素。然而，关于肠道菌群对心血管疾病（CVD）的影响存在争议。目前的证据表明，肠道微生物群是心血管疾病风险的双刃剑，其影响很大程度上取决于肠道微生物群的代谢产物。氧化三甲胺（TMAO）作为肠道菌群的代谢产物之一，一直与较高的心血管疾病风险相关。已经出现了一些研究，提供了关于中药通过调节肠道菌群治疗心血管疾病的安全性和有效性的早期证据。在本文中，我们回顾和解读现有证据，并探讨肠道菌群作为中药预防心血管疾病（CVD）新治疗靶点的潜力。
